🇺🇸 FDA
Pipeline program

Xingnaojing injection

2018YFC1705001-05-02

Approved small_molecule active

Quick answer

Xingnaojing injection for Ischemic Stroke, Acute is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Ischemic Stroke, Acute
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials